Rein Therapeutics prices $50M public offering of 50M shares at $1.00/share

Rein Therapeutics, Inc.

Gross proceeds $50M from 50M shares at $1.00; net proceeds ~$46.1M after discounts and expenses.
Underwriter granted 45-day option for up to 7.5M additional shares; warrants for 3% of sold shares at $1.50.
Bios entities defer conversion of 12,232 Series X preferred shares and lock-up through April 2029; receive 3M warrants at $1.00.
Proceeds to fully fund Phase 2 trial of LTI-03 in IPF; cash runway extended into 2028.
Konik Capital Partners (T.R. Winston) acts as sole book-running manager.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Rein Therapeutics, Inc. entered into Underwriting Agreement with Konik Capital Partners, LLC valued at $1.00 per share, before underwriting discounts and commissions (effective 2026-04-30).

Action: entry
Agreement: underwriting
Counterparty: Konik Capital Partners, LLC
Value: $1.00 per share, before underwriting discounts and commissions
Effective: 2026-04-30

Exact text from the filing

On April 30, 2026, Rein Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Konik Capital Partners, LLC, a division of T.R. Winston & Company, LLC, acting as sole book-running manager, relating to the issuance and sale of 50,000,000 shares of the Company’s common stock, par value $0.001 per share (the “Offering”).

View on SEC.gov

Browse all material agreements →

Rein Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-204006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.